caa a22 4500 465789366 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00216937 doi (NATIONALLICENCE)springer-10.1007/BF00216937 Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study [Elektronische Daten] [Neill Iscoe, Elizabeth Eisenhauer, Audley Bodurtha] Summary: The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily × 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxicity was observed and was not obviously related to the dose of trimetrexate. No responses were seen in 18 patients. We did not find trimetrexate given as described to be effective in metastatic malignant melanoma. Kluwer Academic Publishers, 1990 trimetrexate nationallicence antifols nationallicence melanoma nationallicence Iscoe Neill University of Toronto, Toronto, Ontario aut Eisenhauer Elizabeth Queen's University, Kingston, Ontario aut Bodurtha Audley Dalhousie University, Halifax, Nova Scotia, Canada aut Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 121-123 0167-6997 8:1<121 1990 8 10637 https://doi.org/10.1007/BF00216937 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00216937 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Iscoe Neill University of Toronto, Toronto, Ontario aut NATIONALLICENCE 700 1- Eisenhauer Elizabeth Queen's University, Kingston, Ontario aut NATIONALLICENCE 700 1- Bodurtha Audley Dalhousie University, Halifax, Nova Scotia, Canada aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 121-123 0167-6997 8:1<121 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer